p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia

Journal of B.U.ON.

Volumn 15, Issue 1, 2010, Pages 101-106

  Malisic, Emina ^a   Jankovic, R ^a   Slavkovic, D ^a   Milovic Kovacevic, M ^a   Radulovic, S ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Codon 72 polymorphism; Ovarian carcinoma; p53 mutations

Indexed keywords

ARGININE; PROLINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CAUSE OF DEATH; CODON; DISTANT METASTASIS; DNA ISOLATION; EARLY CANCER; EXON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; P53 GENE; POLYMERASE CHAIN REACTION; PROGNOSIS; REGIONAL METASTASIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SERBIA; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CODON; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SERBIA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950963460     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Welsh JB, Zarrinkar PP, Sapisoso LM et al. Analysis of gene expression profile in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001; 98: 1176-1181.
2. Wenham RM, Lancaster JM, Berchuck A. Molecular aspect of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002; 16: 483-497.
3. Sionov RV, Haupt Y. The cellular response to p53 : the decision between life and death. Oncogene 1999; 18: 6145-6157.
4. Schuijer M, Berns EM. TP53 and Ovarian Cancer. Hum Mutat 2003; 21: 285-291.
5. Shih I-M, Kurman RJ. Ovarian Tumorigenesis. A Proposed Model Based on Morphological and Molecular Genetic Analysis. Am J Pathol 2004; 164: 1511-1518.
6. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
7. Powell B, Soong R, Iacopetta B et al. Prognostic significance of mutations to different structural and functional region of the p53 gene in breast cancer. Clin Cancer Res 2000; 6: 443-451. (Pubitemid 30111462)
8. Wang Y, Helland A, Holm R et al. TP53 mutations in early-stage ovarian carcinoma: relation to long-term survival. Br J Cancer 2004; 90: 678-685. (Pubitemid 38297210)
9. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and bilogocally. Mol Cell Biol 1999; 19: 1092-1100.
10. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108: 196-199. (Pubitemid 37541770)
11. Ueda M, Terai Y, Kanda K et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 2006; 100: 173-178. (Pubitemid 41815069)
12. Agorastos T, Masouridou S, Lambropoulos AF et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 2004; 13: 277-280. (Pubitemid 39096080)
13. Santos AM, Sousa H, Pinto D et al. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 2006; 42: 958-963.
14. Santos AM, Sousa H, Portela C et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340: 256-262. (Pubitemid 41827674)
15. Galic V, Willner J, Wollan M et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 2007; 46: 239-247. (Pubitemid 46155319)
16. Ouellet V, Zietarska M, Portelance L et al. Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 2008; 8: 1-18.
17. Colombo N, Van Gorp T, Parma G et al. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159-179.
18. Partridge EE, Barnes MN. Epithelial Ovarian Cancer: Prevention, Diagnosis, and Treatment. CA Cancer J Clin 1999; 49: 297-320.
19. Guppy AE, Rustin GJ. CA 125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002; 7: 437-443.
20. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121: 124-132.
21. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004; 52: 103-116.
22. Köbel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 2008; 10: e22.
23. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih UeM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198: 351-356.
24. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004; 93: 301-306. (Pubitemid 38507593)
25. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. p53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001 ; 194: 68-75.
26. Guan X, Lang J, Bian M. Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 1998; 33: 165-167.
27. Høgdall EV, Høgdall CK, Christensen L et al. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 2002; 22: 1859-1864. (Pubitemid 34839209)
28. Gadducci A, Di Cristofano C, Zavaglia M et al. p53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 2006; 26: 687-693. (Pubitemid 43206035)